The pharmaceutical industry is abuzz with the exciting news of Corbus Pharmaceuticals Holdings, Inc. releasing updated Phase 1 clinical data for their revolutionary drug, SYS-6002 (CRB-701). This groundbreaking advance in cancer treatment is set to be presented at the prestigious 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, generating significant interest and anticipation among experts and researchers alike.
Facts:
Corbus Pharmaceuticals Holdings, Inc. recently unveiled abstract No. 3151 for a poster presentation at the 2024 ASCO Annual Meeting, scheduled to take place from May 31 to June 4 in Chicago. The abstract
Comments